| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 16 | 2024 | 1781 | 1.630 |
Why?
|
| Dacarbazine | 6 | 2017 | 505 | 1.180 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2021 | 2417 | 0.920 |
Why?
|
| Dysmenorrhea | 1 | 2023 | 16 | 0.870 |
Why?
|
| Kidney Neoplasms | 5 | 2021 | 3153 | 0.830 |
Why?
|
| Benzimidazoles | 2 | 2015 | 442 | 0.780 |
Why?
|
| Integrins | 3 | 2010 | 278 | 0.690 |
Why?
|
| Tuberous Sclerosis | 1 | 2021 | 144 | 0.660 |
Why?
|
| Birt-Hogg-Dube Syndrome | 1 | 2017 | 7 | 0.600 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2017 | 609 | 0.600 |
Why?
|
| DNA Modification Methylases | 2 | 2015 | 176 | 0.590 |
Why?
|
| DNA Repair Enzymes | 2 | 2015 | 236 | 0.560 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2017 | 514 | 0.560 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2023 | 7792 | 0.550 |
Why?
|
| Liver Neoplasms | 3 | 2023 | 4811 | 0.520 |
Why?
|
| Brain Neoplasms | 9 | 2024 | 4994 | 0.500 |
Why?
|
| Interferon-beta | 4 | 2008 | 109 | 0.460 |
Why?
|
| Image Enhancement | 2 | 2015 | 555 | 0.450 |
Why?
|
| Laparoscopy | 1 | 2023 | 1298 | 0.440 |
Why?
|
| Whole Body Imaging | 1 | 2014 | 114 | 0.440 |
Why?
|
| Contrast Media | 4 | 2022 | 1510 | 0.430 |
Why?
|
| Gadolinium | 1 | 2014 | 172 | 0.430 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2015 | 233 | 0.420 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2024 | 3929 | 0.410 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2015 | 1905 | 0.360 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2018 | 7958 | 0.340 |
Why?
|
| Immunoconjugates | 2 | 2024 | 314 | 0.340 |
Why?
|
| Blood-Brain Barrier | 4 | 2022 | 250 | 0.330 |
Why?
|
| Radiation Dosage | 4 | 2023 | 1043 | 0.330 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2009 | 267 | 0.310 |
Why?
|
| Diagnostic Imaging | 2 | 2018 | 1178 | 0.310 |
Why?
|
| Cell Movement | 3 | 2010 | 2504 | 0.300 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 3 | 2024 | 437 | 0.290 |
Why?
|
| Multidetector Computed Tomography | 2 | 2022 | 148 | 0.290 |
Why?
|
| DNA Methylation | 3 | 2019 | 2761 | 0.290 |
Why?
|
| Multiple Sclerosis | 5 | 2009 | 372 | 0.280 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2008 | 39 | 0.280 |
Why?
|
| src-Family Kinases | 1 | 2009 | 487 | 0.270 |
Why?
|
| Adjuvants, Immunologic | 3 | 2007 | 692 | 0.260 |
Why?
|
| Brain | 7 | 2022 | 4257 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2024 | 5421 | 0.260 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 2 | 2017 | 163 | 0.250 |
Why?
|
| Mice, Nude | 6 | 2021 | 4360 | 0.250 |
Why?
|
| Humans | 49 | 2024 | 272087 | 0.250 |
Why?
|
| Bystander Effect | 1 | 2024 | 22 | 0.240 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 3704 | 0.210 |
Why?
|
| Quinolones | 1 | 2024 | 163 | 0.210 |
Why?
|
| Pelvic Pain | 1 | 2023 | 47 | 0.210 |
Why?
|
| Myometrium | 1 | 2023 | 83 | 0.210 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 5248 | 0.200 |
Why?
|
| Ataxia Telangiectasia | 1 | 2022 | 62 | 0.200 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2024 | 327 | 0.200 |
Why?
|
| Cell Line, Tumor | 9 | 2024 | 14881 | 0.200 |
Why?
|
| Abdomen | 1 | 2023 | 348 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2024 | 3671 | 0.190 |
Why?
|
| Luminescent Measurements | 1 | 2021 | 159 | 0.190 |
Why?
|
| Isoxazoles | 1 | 2021 | 79 | 0.190 |
Why?
|
| Indazoles | 2 | 2020 | 310 | 0.190 |
Why?
|
| Azabicyclo Compounds | 1 | 2021 | 40 | 0.190 |
Why?
|
| Pyrimidines | 3 | 2020 | 3664 | 0.180 |
Why?
|
| ErbB Receptors | 3 | 2024 | 2383 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2022 | 4963 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 157 | 0.180 |
Why?
|
| Female | 25 | 2024 | 149288 | 0.170 |
Why?
|
| Sulfonamides | 2 | 2020 | 1919 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2019 | 126 | 0.170 |
Why?
|
| Animals | 17 | 2024 | 62822 | 0.160 |
Why?
|
| Prospective Studies | 4 | 2023 | 13410 | 0.160 |
Why?
|
| Signal Transduction | 5 | 2024 | 12223 | 0.160 |
Why?
|
| Mice | 14 | 2024 | 36053 | 0.160 |
Why?
|
| Pyrazines | 1 | 2021 | 513 | 0.160 |
Why?
|
| Up-Regulation | 3 | 2015 | 2457 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 9101 | 0.150 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2022 | 379 | 0.150 |
Why?
|
| Random Allocation | 2 | 2017 | 746 | 0.150 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 7976 | 0.150 |
Why?
|
| Uterus | 1 | 2023 | 815 | 0.150 |
Why?
|
| DNA Repair | 3 | 2024 | 1912 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 398 | 0.140 |
Why?
|
| Chromones | 1 | 2017 | 121 | 0.140 |
Why?
|
| Adult | 17 | 2023 | 81933 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2024 | 3395 | 0.140 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2017 | 76 | 0.140 |
Why?
|
| Pyridines | 1 | 2024 | 1312 | 0.140 |
Why?
|
| Paraparesis, Tropical Spastic | 2 | 2006 | 7 | 0.140 |
Why?
|
| Quinazolines | 1 | 2021 | 953 | 0.130 |
Why?
|
| Male | 19 | 2023 | 129088 | 0.130 |
Why?
|
| Middle Aged | 14 | 2023 | 90460 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 653 | 0.130 |
Why?
|
| Phthalazines | 1 | 2017 | 263 | 0.130 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 520 | 0.120 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 366 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 845 | 0.120 |
Why?
|
| Iridium Radioisotopes | 1 | 2014 | 57 | 0.120 |
Why?
|
| Pyridazines | 1 | 2017 | 319 | 0.120 |
Why?
|
| Thyrotropin | 1 | 2014 | 125 | 0.120 |
Why?
|
| Antibodies, Blocking | 1 | 2014 | 92 | 0.120 |
Why?
|
| Survivors | 1 | 2019 | 1025 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 1592 | 0.110 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 481 | 0.110 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 31066 | 0.110 |
Why?
|
| Whole-Body Irradiation | 1 | 2014 | 324 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 16612 | 0.110 |
Why?
|
| Retrospective Studies | 9 | 2022 | 39831 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 1547 | 0.110 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2012 | 10 | 0.110 |
Why?
|
| Models, Biological | 3 | 2010 | 3223 | 0.100 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2014 | 320 | 0.100 |
Why?
|
| DNA Damage | 3 | 2017 | 1989 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2016 | 809 | 0.100 |
Why?
|
| Kidney | 1 | 2021 | 2266 | 0.100 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2012 | 89 | 0.100 |
Why?
|
| Imidazoles | 1 | 2017 | 1056 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 4900 | 0.100 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2011 | 28 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1085 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 641 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2024 | 4984 | 0.090 |
Why?
|
| Cell Adhesion | 2 | 2010 | 1041 | 0.090 |
Why?
|
| Heart Valve Diseases | 1 | 2012 | 197 | 0.090 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2011 | 116 | 0.090 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 14653 | 0.090 |
Why?
|
| Fibroblasts | 2 | 2014 | 1670 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 1265 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2009 | 12 | 0.090 |
Why?
|
| Mutation | 3 | 2024 | 15944 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2009 | 30 | 0.090 |
Why?
|
| Osteosarcoma | 1 | 2017 | 948 | 0.090 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2009 | 24 | 0.080 |
Why?
|
| Disease Progression | 2 | 2018 | 6911 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2015 | 605 | 0.080 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2009 | 27 | 0.080 |
Why?
|
| Interferon beta-1b | 2 | 2005 | 6 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 3512 | 0.080 |
Why?
|
| Treatment Outcome | 7 | 2020 | 33909 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2017 | 2119 | 0.080 |
Why?
|
| Cricetulus | 1 | 2009 | 215 | 0.080 |
Why?
|
| Histones | 2 | 2017 | 1514 | 0.080 |
Why?
|
| Endothelium | 1 | 2009 | 162 | 0.080 |
Why?
|
| CHO Cells | 1 | 2009 | 323 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 2009 | 1832 | 0.080 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2009 | 110 | 0.080 |
Why?
|
| Aortic Valve | 1 | 2012 | 484 | 0.080 |
Why?
|
| Aged | 8 | 2019 | 73517 | 0.080 |
Why?
|
| Liver | 1 | 2018 | 3123 | 0.080 |
Why?
|
| Cannabinoids | 1 | 2009 | 43 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 1737 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 6210 | 0.080 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2009 | 163 | 0.080 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 3472 | 0.080 |
Why?
|
| Cricetinae | 1 | 2009 | 793 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2014 | 5788 | 0.070 |
Why?
|
| Brachytherapy | 1 | 2014 | 1005 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2012 | 847 | 0.070 |
Why?
|
| Young Adult | 4 | 2019 | 22142 | 0.070 |
Why?
|
| Genomics | 1 | 2018 | 2830 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 2010 | 666 | 0.070 |
Why?
|
| Central Nervous System | 1 | 2008 | 457 | 0.070 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2006 | 103 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2015 | 1544 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 1133 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2021 | 1470 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 2669 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 680 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 5196 | 0.060 |
Why?
|
| DNA End-Joining Repair | 1 | 2024 | 92 | 0.060 |
Why?
|
| Forearm | 1 | 2003 | 70 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2009 | 774 | 0.050 |
Why?
|
| Hand Deformities, Congenital | 1 | 2003 | 95 | 0.050 |
Why?
|
| Hand | 1 | 2003 | 176 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2006 | 638 | 0.050 |
Why?
|
| Cell Survival | 2 | 2019 | 3074 | 0.050 |
Why?
|
| Luciferases, Firefly | 1 | 2021 | 41 | 0.050 |
Why?
|
| Infusion Pumps | 1 | 2021 | 60 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 4496 | 0.050 |
Why?
|
| Luciferases | 1 | 2021 | 464 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 10750 | 0.040 |
Why?
|
| Neoplasm Proteins | 2 | 2022 | 3363 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2021 | 946 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2018 | 1842 | 0.040 |
Why?
|
| Intestine, Small | 1 | 2022 | 527 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2018 | 206 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 164 | 0.040 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2017 | 78 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2003 | 1313 | 0.030 |
Why?
|
| Gamma Rays | 1 | 2017 | 241 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2018 | 410 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 1566 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 4400 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 7476 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 729 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 5107 | 0.030 |
Why?
|
| Protein Modification, Translational | 1 | 2014 | 5 | 0.030 |
Why?
|
| Miniaturization | 1 | 2014 | 49 | 0.030 |
Why?
|
| Graves Disease | 1 | 2014 | 48 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 4071 | 0.030 |
Why?
|
| Renal Veins | 1 | 2014 | 64 | 0.030 |
Why?
|
| Endothelial Cells | 2 | 2010 | 1049 | 0.030 |
Why?
|
| Transfection | 1 | 2019 | 3166 | 0.030 |
Why?
|
| Computer-Aided Design | 1 | 2014 | 76 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2014 | 327 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 1248 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2015 | 317 | 0.030 |
Why?
|
| Vena Cava, Inferior | 1 | 2014 | 195 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2019 | 7302 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 1439 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2014 | 356 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2014 | 531 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2021 | 5841 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2008 | 2058 | 0.020 |
Why?
|
| Swiss 3T3 Cells | 1 | 2011 | 5 | 0.020 |
Why?
|
| Acetylation | 1 | 2012 | 517 | 0.020 |
Why?
|
| Smad Proteins | 1 | 2011 | 82 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2010 | 119 | 0.020 |
Why?
|
| Equipment Design | 1 | 2014 | 1207 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 259 | 0.020 |
Why?
|
| Transcriptome | 1 | 2019 | 1950 | 0.020 |
Why?
|
| Dermis | 1 | 2010 | 63 | 0.020 |
Why?
|
| Protein Binding | 1 | 2017 | 3528 | 0.020 |
Why?
|
| Methylation | 1 | 2012 | 626 | 0.020 |
Why?
|
| Prognosis | 2 | 2019 | 22555 | 0.020 |
Why?
|
| Algorithms | 1 | 2022 | 3925 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2014 | 650 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 1155 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 721 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 968 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 14 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 2012 | 410 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2014 | 1066 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 455 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 15279 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 123 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 1548 | 0.020 |
Why?
|
| Dogs | 1 | 2011 | 1169 | 0.020 |
Why?
|
| Autocrine Communication | 1 | 2009 | 93 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 271 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2014 | 808 | 0.020 |
Why?
|
| Dronabinol | 1 | 2009 | 41 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 2035 | 0.020 |
Why?
|
| Antigens | 1 | 2009 | 283 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2009 | 278 | 0.020 |
Why?
|
| Cannabidiol | 1 | 2009 | 43 | 0.020 |
Why?
|
| Radiometry | 1 | 2014 | 1017 | 0.020 |
Why?
|
| Time | 1 | 2008 | 186 | 0.020 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2008 | 121 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2012 | 621 | 0.020 |
Why?
|
| Fibrosis | 1 | 2011 | 747 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 5187 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 1718 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 458 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2009 | 243 | 0.020 |
Why?
|
| Interferon beta-1a | 1 | 2007 | 24 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 453 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 5330 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2008 | 615 | 0.020 |
Why?
|
| Exons | 1 | 2010 | 1388 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2085 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 344 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 2298 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 3646 | 0.020 |
Why?
|
| Survival Rate | 1 | 2019 | 12534 | 0.020 |
Why?
|
| HTLV-I Infections | 1 | 2005 | 17 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2015 | 2129 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 3651 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2009 | 906 | 0.020 |
Why?
|
| Antibodies | 1 | 2008 | 819 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2009 | 919 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 3262 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2008 | 669 | 0.020 |
Why?
|
| Age of Onset | 1 | 2007 | 855 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 2219 | 0.010 |
Why?
|
| Viral Load | 1 | 2006 | 482 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2009 | 1176 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 4635 | 0.010 |
Why?
|
| Neoplasms | 1 | 2010 | 15930 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2014 | 6489 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2011 | 1892 | 0.010 |
Why?
|
| Cadaver | 1 | 2003 | 206 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 6783 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2009 | 2621 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 1720 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 3543 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 1327 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2009 | 1575 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6270 | 0.010 |
Why?
|
| Time Factors | 2 | 2007 | 13139 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2005 | 724 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 18051 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 1707 | 0.010 |
Why?
|
| Patient Selection | 1 | 2006 | 2045 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 13993 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2008 | 9500 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2005 | 4513 | 0.010 |
Why?
|